Publication
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (17)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 17
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugCetuximabcivic_curation1.00
- drugPanitumumabcivic_curation1.00
- geneKRAScivic_curation1.00
- genePIK3CAcivic_curation1.00
- genePTENcivic_curation1.00
- variantKRAS G12Acivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
- variantKRAS G12/G13civic_curation1.00
- variantKRAS G12Scivic_curation1.00
- variantKRAS G12Vcivic_curation1.00
- variantKRAS G13Dcivic_curation1.00
- variantKRAS G13Vcivic_curation1.00
- variantPIK3CA E545Kcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPTEN Losscivic_curation1.00
Curated evidence
Evidence citing this paper (26)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 19223544
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G12A2 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID6319In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | submitted | EID6325KRAS G12A was the only variant noted in the primary tumor of one metastatic colorectal cancer patient who experienced stable disease following treatment with anti-epidermal growth factor receptor (EGF… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| KRAS G12D1 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID6316In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| KRAS G12/G131 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | accepted | EID6363Mutational analysis of 109 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| KRAS G12S2 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID6314In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN we… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Does Not Support Resistance | 1 | rejected | EID6324In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G12S was the only … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| KRAS G12V2 | ||||||||
| Cetuximab + PanitumumabCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | submitted | EID6313KRAS G12V was the only variant noted in the primary tumors of two metastatic colorectal cancer patients who experienced stable disease following treatment with anti-epidermal growth factor receptor (E… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID6323In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| KRAS G13D2 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Does Not Support Resistance | 2 | accepted | EID6320In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID6322In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| KRAS G13V2 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID6312In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN we… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID6321KRAS G13V was the only variant noted in the metastatic tumor of one metastatic colorectal cancer patient who experienced partial response following treatment with anti-epidermal growth factor receptor… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PIK3CA E542K2 | ||||||||
| (prognostic) | Malignant Colorectal NeoplasmCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | rejected | EID385The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation (P = 0.035). PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | rejected | EID256The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response. PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PIK3CA E545D2 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID4048In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID2353In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PIK3CA E545K3 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID3720In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID387In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN we… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Does Not Support Resistance | 2 | accepted | EID2037In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA E545K was the on… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PIK3CA E545V2 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID3725In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID2073In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PIK3CA H1047R2 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Resistance | 2 | accepted | EID258In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN we… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| 〃 | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID388In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN we… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PIK3CA Mutation1 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | accepted | EID6362Mutational analysis of 110 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| PTEN Loss2 | ||||||||
| Cetuximab + PanitumumabSubstitutes | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | accepted | EID6315In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a s… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |
| 〃 | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Resistance | 1 | submitted | EID6361In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PTEN protein expression… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC | civic |